Table 1.
Characteristics at discharge by 1-month post-discharge haematocrit change
| Quartile 1 (n = 452) Most haemodilution |
Quartile 2 (n = 329) | Quartile 3 (n = 171) | Quartile 4 (n = 346) Least haemodilution |
P-value | |
|---|---|---|---|---|---|
| Hct levels | |||||
| Absolute ΔHct, range (%) | −21, −4 | −3, −2 | −1,2 | 2, 14 | |
| Hct (%), mean ± SD | 46 ± 6 | 43 ± 5 | 42 ± 5 | 40 ± 6 | <0.01 |
| Patient characteristics | |||||
| Age (years), mean ± SD | 65 ± 12 | 65 ± 12 | 65 ± 12 | 66 ± 12 | 0.23 |
| Male sex, n (%) | 349 (77) | 251 (76) | 347 (7.4) | 273 (79) | 0.35 |
| SBP (mmHg), mean ± SD | 114 ± 16 | 116 ± 16 | 116 ± 17 | 115 ± 18 | 0.37 |
| HR (bpm), mean ± SD | 75 ± 12 | 73 ± 11 | 74 ± 13 | 75 ± 12 | 0.31 |
| Weight (kg), mean ± SD | 78 ± 17 | 81 ± 18 | 81 ± 18 | 82 ± 19 | 0.02 |
| LVEF (%), mean ± SD | 27 ± 8 | 28 ± 8 | 28 ± 8 | 28 ± 8 | 0.58 |
| BNP (pg/mL), median (25th-75th) | 372 (131–809) | 429 (177–979) | 404 (176–980) | 632 (271–1193) | <0.01 |
| Creatinine (mg/dL), median (25th-75th) | 1.2(1.0–1.5) | 1.2 (1.0–1.5) | 1.2 (1.0–1. 6) | 1.3 (1.0–1.7) | 0.51 |
| BUN (mg/dL), median (25th-75th) | 27 (21–38) | 27 (21–37) | 27 (20 −38) | 27 (21–41) | 0.66 |
| Diabetes mellitus, n (%) | 137 (30) | 122 (37) | 175 (37) | 138 (40) | 0.03 |
| Chronic kidney disease, n (%) | 85 (19) | 69 (21) | 126 (27) | 104 (30) | <0.01 |
| Prior HF Hospitalization, n (%) | 348 (77) | 260 (80) | 377 (81) | 263 (76) | 0.34 |
| Coronary artery disease, n (%) | 305 (68) | 221 (67) | 349 (74) | 250 (72) | 0.07 |
| Hypertension, n (%) | 296 (66) | 228 (69) | 354 (75) | 250 (72) | 0.01 |
| Hyperlipidaemia, n (%) | 205 (45) | 135 (41) | 223 (4.8) | 173 (50) | 0.10 |
| Signs/symptoms of HF, n (%) | |||||
| Peripheral oedema | 87 (24) | 88 (34) | 133 (37) | 136 (51) | <0.01 |
| Rales | 60 (17) | 43 (17) | 74 (21) | 60 (23) | 0.20 |
| Dyspnoea | 59 (17) | 37(14) | 53 (15) | 54 (20) | 0.24 |
| JVP >10 cm | 19(5) | 9(4) | 14(4) | 16(6) | 0.46 |
| Medical therapy, n (%) | |||||
| ACEI/ARB | 386 (86) | 297 (90) | 403 (86) | 283 (82) | 0.02 |
| Beta-blocker | 327 (73) | 257 (78) | 349 (7.4) | 259 (75) | 0.44 |
| MRA | 310 (69) | 211 (64) | 314 (67) | 208 (60) | 0.05 |
| Diuretic | 431 (96) | 313 (95) | 443 (94) | 331 (96) | 0.39 |
| Event rates, n (%) | |||||
| All-cause mortality | 104 (23) | 60 (18) | 93 (20) | 78 (23) | 0.31 |
| CVM or HF hospitalization | 174 (39) | 116 (35) | 177 (38) | 141 (41) | 0.52 |
| CVM | 85 (19) | 42 (13) | 77 (16 | 58 (17) | 0.16 |
| HF hospitalization | 123 (27) | 83 (25) | 140 (30) | 108 (31) | 0.30 |
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BUN, blood urea nitrogen; CVM, cardiovascular mortality; Hct, haematocrit; HF, heart failure; HR, heart rate; JVP, jugular venous pressure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; SBP, systolic blood pressure; SD, standard deviation.